ADIL

News EXCLUSIVE: Adial Pharmaceuticals Moves Forward To Second Cohort In Pharmacokinetics Study of AD04 For Alcohol Use Disorder - Benzinga

14d ago

News Adial Pharmaceuticals reports Q1 results

22d ago

SEC filing ADIL Reports $2.0M Net Loss, $4.6M Cash, R&D Expenses Down 42% to $433K, G&A Up 3% to $1.6M

22d ago

SEC filing ADIL RSAs: CEO Cary Claiborne 37,985 shares; CFO Vinay Shah 17,325 shares; COO Tony Goodman 26,510 shares; Directors Kevin Schuyler & Robertson Gilliland 9,185 RSAs each; Director Kermit Anderson options 9,185 @ $1.64; RSAs vest 1yr or Change of Control

53d ago

SEC filing ADIL Reports $0 Revenue, -$12.3M Net Loss, +15% IP Patents, Molteni Europe Deal

88d ago

News Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045

139d ago

News Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery

141d ago

Scanner Unusual volume (z=3.5)

168d ago